Drug intelligence / Profile preview

KYV-102

Development stage: Preclinical
Lead developer: Kyverna Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KYV-102 is a next-generation, fully human CD19 CAR T-cell therapy developed by Kyverna Therapeutics. It is designed to target the CD19 protein on B-cells, leading to their depletion, which is a therapeutic strategy for various autoimmune diseases. Kyverna Therapeutics is accelerating the clinical development of KYV-102, and has partnered with Multiply Labs and ElevateBio to enhance its manufacturing processes through automation and advanced process development.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on KYV-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KYV-102.

Explore the full profile